Compare Manhattan Associates Inc (MANH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Tango Therapeutics Inc. — how do they compare? Manhattan Associates Inc trades at $216.88 (market cap $12.99B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Manhattan Associates Inc is far larger — about 3.5× Tango Therapeutics Inc.'s market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 11 Days and Tango Therapeutics Inc. for 0 Days on average.
| MANH | TNGX | |
|---|---|---|
Market Cap | $12.99B | $3.75B |
Volume | 546,880 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $223.76 | $32.90 |
52-Week Low | $120.88 | $7.50 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $12.85B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $222.71, up 2.21% today, with a bullish technical signal and strong profitability metrics including a 96.38% ROE. Recent earnings have consistently beaten expectations, and the company launched new Editions solutions to expand market access. However, high valuation ratios and a legal investigation pose headwinds.
The outlook remains positive with 80% analyst buy ratings and a $219.25 consensus target, but risks include elevated P/E of 63.81 and potential fiduciary breach concerns. Earnings growth and product innovation are key catalysts, yet investors should weigh valuation against legal and competitive pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
